Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia

Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia: Cross-sectional Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07354191

Enrollment

Registered

2026-01-21

Start date

2023-01-15

Completion date

2025-11-06

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.

Detailed description

AIHAs may be primary or associated with lymphoproliferative and autoimmune diseases, infections, immunodeficiencies, solid tumors, transplants, and drugs. The direct antiglobulin test is the cornerstone of diagnosis, allowing the distinction into warm forms (wAIHA), cold agglutinin disease (CAD), and other more rare forms. Multiple myeloma (MM), on the other hand, is characterized by a clonal expansion of plasma cells in bone marrow, causing bone tissue destruction, renal failure and hematopoietic suppression. Although the association of MM and anemia is common, AIHA as the anemic manifestation of MM is rare. This prospective study will be conducted to detect the presence of AIHA in MM patients and its impact on clinical presentation and outcome of the disease.

Interventions

DIAGNOSTIC_TESTdirect antiglobulin test (DAT)

Serum sample

DIAGNOSTIC_TESTIndirect antiglobulin test (IAT)

Serum sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of multiple myeloma

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
Measure prevalence of AIHA in MM patients .	baseline	Number of MM patients with AIHA
Detect impact on International Prognostic Scoring System	baseline	relation of the presence of AIHA to the scoring system of the patient
Detect impact on outcome	through study completion, an average of 1 year	Number of patient with AIHA regarding in each response group CR, PR, PD

Secondary

Measure	Time frame	Description
Identify complications of AIHA IN MM	through study completion, an average of 1 year	number pf complications related to AIHA in each patien

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026